Chronic Obstructive Pulmonary Disease Exacerbation Clinical Trial
— SPIROMINDOfficial title:
A Pilot Randomized Controlled Trial to Examine the Feasibility and Effectiveness of a Brief Digital Mindfulness-based Intervention for COPD Patients
Verified date | March 2024 |
Source | Karl Landsteiner Institute for Lung Research and Pneumological Oncology |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this pilot study is to assess the feasibility of a brief digital mindfulness-based intervention for COPD patients and its effectiveness regarding the reduction of psychological distress as well as stress.
Status | Completed |
Enrollment | 30 |
Est. completion date | March 27, 2023 |
Est. primary completion date | December 5, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years and older |
Eligibility | Inclusion criteria: 1. spirometry confirmed (FEV1<80%) COPD diagnosis 2. psychological distress (as assessed by the Hospital Anxiety and Depression Scale): HADS-A = 8 OR HADS-D = 8 OR* 3. age = 40 years 4. ability to understand German 5. physical and mental capability to attend the intervention, judged by the treating physician 6. life expectancy > 6 months as judged by treating physician 7. ability to use a smartphone 8. ability not to smoke for the duration of the measurement time points (2-3 hours) (This criterion has been added later, because we learned that this was a problem for some participants. However, smoking during the measurements heavily affects biomarker data and the subjective stress response to a stress induction protocol.) Exclusion Criteria: 1. auditory impairment 2. active asthma diagnosis ("Regardless of your COPD, have you had allergies and asthma in childhood or adolescence and needed medication for them at that time?" If no: No active asthma. If yes: "Is your asthma active and a problem now in addition to your COPD and do you currently need asthma medications because of it?" If no: No active asthma. If yes: exclusion)** 3. any other known severe comorbidities such as heart failure (LVF<35%), uncontrolled diabetes, concomitant cancer, stroke, unstable coronary heart disease, respiratory failure 4. history of/current severe psychological disorder (e.g. schizophrenia, severe cognitive impairment) 5. current acute exacerbation of COPD 6. any other relevant acute health crisis interfering with the study intervention (e.g. Covid-19) 7. receiving any psychosocial treatment (e.g. psychotherapy) 8. regular other systematic mind-body-practice (*) When the only exclusion criterion was the HADS, which was often the case, we contacted the participants two months later to screen them again and included them, if they were eligible. (**) We further specified this criterion, as we learned that many patients were told to probably have asthma without them knowing exactly if they had an active asthma diagnosis. |
Country | Name | City | State |
---|---|---|---|
Austria | Klinik Ottakring | Vienna |
Lead Sponsor | Collaborator |
---|---|
Karl Landsteiner Institute for Lung Research and Pneumological Oncology | Klinik Floridsdorf, Klinik Ottakring, Therme Wien Med (Ambulant Pulmonary Rehabilitation), University of Vienna |
Austria,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Psychological distress | Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983; German version Herrmann-Lingen et al., 2011), scores: 0-42, lower scores indicate improvement, interpreting both subscales for anxiety and depression | baseline - 4 weeks | |
Primary | Psychological distress | Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983; German version Herrmann-Lingen et al., 2011), scores: 0-42, lower scores indicate improvement, interpreting both subscales for anxiety and depression | baseline - 8 weeks | |
Primary | Patient's experiences with the digital MBI | patients' experiences assessed in the exit interview (qualitative and quantitative data) | 8 weeks | |
Secondary | Chronic stress | assessed by Perceived Stress Scale (PSS-10; Cohen & Williamson, 1988; German version Klein et al., 2016), scores 0-40, lower scores indicate improvement | baseline, 4 weeks, 8 weeks, 4 months, 6 months | |
Secondary | Health related quality of life | Chronic Respiratory Questionnaire (CRQ-SAS; German version Schünemann et al., 2003), scores: 20-140, higher scores indicate improvement | baseline, 4 weeks, 8 weeks, 4 months, 6 months | |
Secondary | Health status impairment | COPD Assessment Test (CAT; Jones et al., 2009), scores 0-40, lower scores indicate improvement | baseline, 4 weeks, 8 weeks, 4 months, 6 months | |
Secondary | Fatigue | Multidimensional Fatigue Inventory (MFI-20; German version Schwarz, Krauss, & Hinz, 2003), scores 0-80, items have different polarity | baseline, 4 weeks, 8 weeks, 4 months, 6 months | |
Secondary | Mindfulness | Freiburger Mindfulness Inventory short form (FMI short form; Walach, Buchheld, Buttenmüller, Kleinknecht, & Schmidt, 2006), scores 0-42, higher scores indicate improvement | baseline, 4 weeks, 8 weeks, 4 months, 6 months | |
Secondary | Self-compassion | Self-Compassion Scale short form (SCS short form; Raes, Pommier, Neff, & Van Gucht, 2011; German version Hupfeld & Ruffieux, 2011), scores 12-60, items have different polarity | baseline, 4 weeks, 8 weeks, 4 months, 6 months | |
Secondary | Breathlessness catastrophizing | Breathlessness Catastrophizing Scale (BCS; Solomon et al., 2015; German version adapted analogue to Pain Catastrophizing Scale Meyer, Sprott, & Mannion, 2008), scores 0-52, lower scores indicate improvement | baseline, 4 weeks, 8 weeks, 4 months, 6 months | |
Secondary | Stress reactivity | the reactivity to stress assessed via examining heart rate variability (RMSSD) during the exposure to a mental stressor (stroop test) | baseline, 4 weeks, 8 weeks, 4 months, 6 months | |
Secondary | Stress reactivity | the reactivity to stress assessed via examining skin conductance level during the exposure to a mental stressor (stroop test) | baseline, 4 weeks, 8 weeks, 4 months, 6 months | |
Secondary | Hair cortisol | concentration of hair cortisol (as biomarker for chronic stress) | baseline, 8 weeks, 4 months, 6 months | |
Secondary | Psychological distress | Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983; German version Herrmann-Lingen et al., 2011), scores: 0-42, lower scores indicate improvement | baseline, 4 months, 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05008081 -
The CATALINA Study
|
||
Completed |
NCT06118684 -
Clinical Trial to Assess Effect of Verapamil on Systemic Exposure of EP395 and Effect of EP395 on Systemic Exposure of Midazolam and Digoxin
|
Phase 1 | |
Recruiting |
NCT05808621 -
Muscle Oxygenation in Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT05769738 -
The Addition of Inhaled Furosemide to Standard Treatment of COPD Exacerbation
|
Phase 3 | |
Recruiting |
NCT04816695 -
Volatolom Variation in Severe COPD During Hospitalization for Exacerbation and After Hospitalization (VOC-BPCO-Exa)
|
N/A | |
Completed |
NCT05991778 -
Bioelectrical Impedance in Monitoring Hyperhydration and Polyneuromyopathy in Critically Ill Patients
|
||
Completed |
NCT05079009 -
Effects of Blood Pulsatility on Von Willebrand Factor During ECCO2R
|
N/A | |
Not yet recruiting |
NCT06105814 -
Improved Diagnostics, Treatment and Follow-up of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT05699720 -
Acute Exacerbation of COPD and Nebulized Magnesium Sulphate
|
N/A | |
Recruiting |
NCT04223050 -
Comparing Mortality for Low vs High Peripheral Oxygen Saturation in COPD-patients With Acute Exacerbation
|
Phase 4 | |
Terminated |
NCT04828837 -
Bubble PEP Training Among Patient With Chronic Obstructive Pulmonary Disease in Pulmonary Function Effects
|
N/A | |
Completed |
NCT05776654 -
Wearable Devices in the Recovery Phase of Acute Exacerbations of COPD (AECOPDs)
|
||
Completed |
NCT05691387 -
Comparison of Active Cycle of Breathing Technique and Pursed Lip Breathing With TheraPep
|
N/A |